Gilead Sciences, Inc. (NASDAQ:GILD) delivered strong fiscal Q2 2026 results, with total revenue rising 10% year over year to ...

In addition to projections of over a half million potential new HIV infections from persistent disruption, US global health security may be threatened by downstream effects of the cuts, expert says.

Gilead's twice-yearly shot reduced HIV infections by 96% in a second large study, the company said. The data sets the stage for likely FDA approval of lenacapavir for HIV prevention. Shares rose 3 ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced that the U.S. Food and Drug Administration (FDA) has approved Tivicay PD ...

It's a twice-a-year injection that is remarkably effective in preventing an HIV infection. Distribution is starting. But questions are being raised about getting it to the areas that need it most.

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. A new sequential immunization strategy shows strong promise for an HIV vaccine, a ...

As of July 2026, there have been 34 newly diagnosed cases of HIV this year and 50% are reported among individuals who inject drugs.

MANILA, Philippines — The Philippines has gone from having one of the lowest estimated rates of new HIV infections among ...

For years, Philip Goulder has been obsessed with a particularly captivating idea: In the hunt for an HIV cure, could children hold the answers? Starting in the mid-2010s, the University of Oxford ...

In the early decades of the global response to HIV/AIDS, the focus was on saving lives. And rightly so: without antiretroviral treatment (ART), people lived less than a year, on average, from the ...

John Eliasu Mahama, Acting Director of Policy and Planning at the Ghana AIDS Commission (GAC), has called on institutions to ...